Companies: 10,795·Total market cap: $144.5T
Ambrx Biopharma Inc.

Ambrx Biopharma Inc.

AMAMNYSEHealthcare
$28.00
+$0.02(+0.07%)
Market Cap$1.8B
P/E Ratio—
52W High$28.15
52W Low$6.55
SEC Filings

Ambrx Biopharma Inc. (AMAM) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001836056 · AMAM · NYSE · as of Jun 8, 2026

Filing snapshot

164
Total Filings
25-NSE
Latest Form
2024-03-07
Most Recent
2023
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001836056 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-03-30
Fiscal Year End
Mar 30, 2023
Accession No.
0000950170-23-010930
Primary Document
amam-20221231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001836056 · Accession 0000950170-23-010930

Latest Key Filings

10-QQuarterly Report
10-Q
2023-08-09
View 10-Q on SEC
8-KCurrent Report
8-K
2023-10-12Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
25-NSE25-NSE
25-NSE
2024-03-07
View
SC 13G/ABeneficial Ownership Report (Amended)
SC 13G/A
2024-02-09
View
15-12G15-12G
15-12G
2023-10-23
View
S-8 POSS-8 POS
S-8 POS
2023-10-12
View
S-8 POSS-8 POS
S-8 POS
2023-10-12
View
S-8 POSS-8 POS
S-8 POS
2023-10-12
View
S-8 POSS-8 POS
S-8 POS
2023-10-12
View
25-NSE25-NSE
25-NSE
2023-10-12
View
8-KCurrent Report
8-K
2023-10-12
View
8-KCurrent Report
8-K
2023-10-10
View
SC 13GBeneficial Ownership Report
SC 13G
2023-10-10
View
8-KCurrent Report
8-K
2023-10-06
View
SC 13GBeneficial Ownership Report
SC 13G
2023-09-25
View
8-KCurrent Report
8-K
2023-09-25
View
DEFM14ADEFM14A
DEFM14A
2023-09-15
View
Showing 1–15 of 140 filingsForm 4 / 144 hidden· 164 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001836056  |  Exchange: NYSE · Healthcare

Ambrx Biopharma Inc. (NYSE: AMAM) has submitted 164 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2023. As a Healthcare sector company with CIK 0001836056, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Ambrx Biopharma Inc.'s most comprehensive regulatory disclosure. The most recent Ambrx Biopharma Inc. 10-K was filed on 2023-03-30 for fiscal year ending 2023. Historical AMAM 10-K annual reports are available from 2021 through 2023.

Investors researching Ambrx Biopharma Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
DICE SEC Filings →BLU SEC Filings →FUSN SEC Filings →BIESF SEC Filings →PNT SEC Filings →EQRX SEC Filings →NAGE SEC Filings →KDMN SEC Filings →
→ AMAM Financials→ AMAM Earnings→ AMAM Insider Trades

Frequently Asked Questions

AMAM SEC Filings · 8 questions

Ambrx Biopharma Inc. (AMAM) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 164 filings and access original documents at no cost. Ambrx Biopharma Inc.'s CIK is 0001836056.

AMAM SEC filingsAmbrx Biopharma Inc. SEC documentsfind AMAM 10-K